Aidoc vs Viz.ai
The two triage giants answer different questions. Viz.ai answers what happens after the finding: its origin product took the first ever FDA De Novo authorization for computer aided triage and notification, and the platform's distinguishing mechanism is mobilization, a mobile app that alerts and connects the treating team rather than only flagging a scan, now spanning more than 50 cleared algorithms across CT, ECG, and echocardiography at over 1,700 hospitals. Aidoc answers how a health system governs many findings at once: aiOS handles normalization, monitoring, and governance as an operating system, and its January 2026 clearance consolidated 14 abdomen CT indications into what it describes as the first comprehensive AI triage solution, built on its CARE foundation model with a mean sensitivity of 97 percent and specificity of 98 percent in the FDA reviewed pivotal study. If your failure mode is the minutes between detection and the team assembling, start with Viz. If your failure mode is running multi condition AI without re architecting infrastructure, start with Aidoc.
- Platform governance is the buy: aiOS handles data normalization, continuous performance monitoring, and governance so multi condition AI runs without re architecting infrastructure, with more than 100 million patient cases reported analyzed.
- Consolidated clearance economics: the January 2026 clearance brought 14 abdomen CT indications into a single workflow on the CARE foundation model, with the company reporting roughly an order of magnitude reduction in false alerts against single condition tools.
- The pivotal numbers are on the regulatory record: mean sensitivity of 97 percent and mean specificity of 98 percent for the newly cleared indications per the FDA reviewed study.
- Team mobilization is the mechanism you are buying: the mobile app alerts and connects specialists the moment a finding lands, which is the workflow that matters when the disease is stroke, hemorrhage, pulmonary embolism, or aortic disease.
- Regulatory first mover with breadth: the first ever FDA De Novo authorization for computer aided triage and notification, now more than 50 cleared algorithms spanning CT, ECG, and echocardiography.
- Deployment footprint as validation: reported at over 1,700 hospitals, one of the widest installed bases in imaging AI.
Side-by-Side
| Axis | A Aidoc |
V Viz.ai |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | — | |
| Deployment Model and Data Residency | — | |
| Commercial Transparency | ||
| Setting and Specialty Coverage | — |
Case volumes, hospital counts, and false alert reduction figures are vendor published; the 97 and 98 percent figures for Aidoc's 2026 clearance come from the FDA reviewed pivotal study as reported by the company. Neither vendor publishes pricing. Security certification is Not Rated on Viz.ai's record and several Aidoc axes remain unassessed in this index; the side by side below shows exactly which, and buyers should request current compliance documentation directly.